MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
48.19
+0.14 (0.29%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.

It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.

MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics
MoonLake Immunotherapeutics logo
Country Switzerland
Founded 2021
Industry Biotechnology
Sector Healthcare
Employees 50
CEO Jorge da Silva

Contact Details

Address:
Dorfstrasse 29
Zug, 6300
Switzerland
Phone 41 415108022
Website moonlaketx.com

Stock Details

Ticker Symbol MLTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001821586
CUSIP Number 61559X104
ISIN Number KY61559X1045
SIC Code 2834

Key Executives

Name Position
Dr. Jorge Santos da Silva Co-Founder, Chief Executive Officer and Director
Dr. Kristian Reich Co-Founder and Chief Scientific Officer
Matthias Bodenstedt Chief Financial Officer
Oliver Daltrop Ph.D. Chief Operations Officer
Carla Bretes Director Investor Relations and Business Development
Nicolas Mosimann General Counsel
Joana Cortez Senior Director Legal and Compliance
Tino Anthamatten Vice President of Marketing, Market Access and Pricing
Luciana Marques Director of Human Resources, People and Culture
Nuala Brennan Chief Clinical Development Officer

Latest SEC Filings

Date Type Title
Oct 8, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 11, 2024 8-K Current Report
Aug 7, 2024 10-Q Quarterly Report
Aug 7, 2024 8-K Current Report
Jun 10, 2024 8-K Current Report
Jun 6, 2024 8-K Current Report
May 13, 2024 UPLOAD Filing
May 7, 2024 10-Q Quarterly Report
May 7, 2024 8-K Current Report
May 7, 2024 10-K/A [Amend] Annual report